$ITCI
Intra-Cellular Therapies, Inc. Stock $itci

$itci Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024006156 Filed on February 22, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$144.9M	$132.1M	$464.4M
YoY Change	52.0%	50.34%	85.51%
Cost Of Revenue	$9.900M	$10.70M	$33.75M
YoY Change	46.64%	57.66%	65.07%
Gross Profit	$135.0M	$121.4M	$430.6M
YoY Change	52.41%	49.72%	87.33%
Gross Profit Margin	93.17%	91.9%	92.73%
Selling, General & Admin	$113.1M	$104.7M	$409.9M
YoY Change	14.32%	10.66%	14.24%
% of Gross Profit	83.79%	86.26%	95.18%
Research & Development	$42.83M	$50.77M	$180.1M
YoY Change	12.65%	49.94%	33.72%
% of Gross Profit	31.74%	41.82%	41.83%
Depreciation & Amortization	$132.0K	$138.0K	$528.0K
YoY Change	-1.49%	-3.5%	-24.57%
% of Gross Profit	0.1%	0.11%	0.12%
Operating Expenses	$165.8M	$166.2M	$623.8M
YoY Change	15.39%	22.85%	21.37%
Operating Profit	-$20.95M	-$44.80M	-$159.4M
YoY Change	-56.7%	-17.35%	-39.54%
Interest Expense	$6.064M	$5.966M	$20.34M
YoY Change	39.43%	76.2%	175.8%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$14.89M	-$28.13M	-$139.0M
YoY Change	-66.2%	-36.1%	-45.74%
Income Tax	$359.0K	$448.0K	$636.0K
% Of Pretax Income
Net Earnings	-$15.25M	-$28.58M	-$139.7M
YoY Change	-65.39%	-35.09%	-45.49%
Net Earnings / Revenue	-10.52%	-21.63%	-30.08%
Basic Earnings Per Share	-$0.16	-$0.30	-$1.46
Diluted Earnings Per Share	-$0.16	-$0.30	-$1.46
COMMON SHARES
Basic Shares Outstanding	96.81M shares	96.24M shares	95.88M shares
Diluted Shares Outstanding	96.88M shares		95.88M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$475.6M	$497.9M	$497.9M
YoY Change	-11.71%	-15.87%	-15.87%
Cash & Equivalents	$139.8M	$147.8M	$147.8M
Short-Term Investments	$335.8M	$350.2M	$350.2M
Other Short-Term Assets	$67.80M	$44.19M	$44.19M
YoY Change	17.91%	-5.86%	-5.86%
Inventory	$15.95M	$11.65M	$11.65M
Prepaid Expenses
Receivables	$131.2M	$114.0M	$114.0M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$690.5M	$667.8M	$667.8M
YoY Change	-2.2%	-9.51%	-9.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.522M	$1.654M	$14.58M
YoY Change	-14.45%	-13.54%	-12.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$7.688M	$7.293M	$45.91M
YoY Change	8839.53%	8380.23%	53288.37%
Total Long-Term Assets	$56.51M	$60.50M	$60.50M
YoY Change	251.77%	259.6%	259.6%
TOTAL ASSETS
Total Short-Term Assets	$690.5M	$667.8M	$667.8M
Total Long-Term Assets	$56.51M	$60.50M	$60.50M
Total Assets	$747.0M	$728.3M	$728.3M
YoY Change	3.44%	-3.51%	-3.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.53M	$11.45M	$11.45M
YoY Change	36.62%	10.17%	10.17%
Accrued Expenses	$123.3M	$112.1M	$112.1M
YoY Change	73.26%	53.89%	53.89%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$134.8M	$123.5M	$123.5M
YoY Change	69.38%	48.43%	48.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$12.74M	$13.33M	$13.33M
YoY Change	-14.87%	-13.88%	-13.88%
Total Long-Term Liabilities	$12.74M	$13.33M	$13.33M
YoY Change	-14.87%	-13.88%	-13.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$134.8M	$123.5M	$123.5M
Total Long-Term Liabilities	$12.74M	$13.33M	$13.33M
Total Liabilities	$147.5M	$136.9M	$136.9M
YoY Change	56.05%	38.66%	38.66%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.632B	-$1.617B
YoY Change	7.29%	9.45%
Common Stock	$2.232B	$2.208B
YoY Change	3.74%	3.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$599.5M	$591.4M	$591.4M
YoY Change
Total Liabilities & Shareholders Equity	$747.0M	$728.3M	$728.3M
YoY Change	3.44%	-3.51%	-3.51%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$15.25M	-$28.58M	-$139.7M
YoY Change	-65.39%	-35.09%	-45.49%
Depreciation, Depletion And Amortization	$132.0K	$138.0K	$528.0K
YoY Change	-1.49%	-3.5%	-24.57%
Cash From Operating Activities	-$34.12M	-$2.059M	-$124.2M
YoY Change	-43.2%	-94.75%	-54.03%
INVESTING ACTIVITIES
Capital Expenditures		-$1.000K	$269.0K
YoY Change		-96.43%	-65.42%
Acquisitions
YoY Change
Other Investing Activities	$16.18M	$47.42M	$105.8M
YoY Change	-198.28%	-5.6%	-182.93%
Cash From Investing Activities	$16.18M	$47.42M	$105.5M
YoY Change	-198.28%	-5.65%	-182.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$9.989M	3.000M	$17.81M
YoY Change	174.42%	37.17%	-96.09%
NET CHANGE
Cash From Operating Activities	-$34.12M	-2.059M	-$124.2M
Cash From Investing Activities	$16.18M	47.42M	$105.5M
Cash From Financing Activities	$9.989M	3.000M	$17.81M
Net Change In Cash	-$7.948M	48.36M	-$848.0K
YoY Change	-89.1%	264.8%	-101.5%
FREE CASH FLOW
Cash From Operating Activities	-$34.12M	-$2.059M	-$124.2M
Capital Expenditures		-$1.000K	$269.0K
Free Cash Flow		-$2.058M	-$124.5M
YoY Change		-94.75%	-54.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-256256000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.72
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.50
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94046670	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81253394	shares
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150365000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93765000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	636000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-139674000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.72
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	95100000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001567514
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36274
CY2023	dei	Entity Registrant Name EntityRegistrantName	Intra-Cellular Therapies, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	36-4742850
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	430 East 29th Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10016
CY2023	dei	City Area Code CityAreaCode	646
CY2023	dei	Local Phone Number LocalPhoneNumber	440-9333
CY2023	dei	Security12b Title Security12bTitle	Common Stock
CY2023	dei	Trading Symbol TradingSymbol	ITCI
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	6000000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	96807191	shares
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Baltimore, Maryland
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147767000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148615000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	350174000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	443290000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1750000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1750000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	114018000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	75189000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	11647000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	23920000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	42443000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	45193000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	667799000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	737957000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1654000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1913000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12928000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14824000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	38621000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	0	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7293000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	86000	usd
CY2023Q4	us-gaap	Assets Assets	728295000	usd
CY2022Q4	us-gaap	Assets Assets	754780000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11452000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10395000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	27944000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	19657000	usd
CY2023Q4	itci	Accrued Customer Programs Current AccruedCustomerProgramsCurrent	53173000	usd
CY2022Q4	itci	Accrued Customer Programs Current AccruedCustomerProgramsCurrent	25621000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	27364000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	22996000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3612000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4567000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	123545000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	83236000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13326000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15474000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	136871000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	98710000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96379811	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96379811	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94829794	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94829794	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	10000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2208470000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2137737000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1617160000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1477486000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	104000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4190000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	591424000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	656070000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	728295000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	754780000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	464370000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	250314000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	83803000	usd
CY2023	itci	Cost Of Product Sales CostOfProductSales	33745000	usd
CY2022	itci	Cost Of Product Sales CostOfProductSales	20443000	usd
CY2021	itci	Cost Of Product Sales CostOfProductSales	8035000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	409864000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	358782000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	272611000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	180142000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	134715000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	88845000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	513940000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	369491000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-285688000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95881729	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95881729	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94046670	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-139674000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-256256000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-284126000	usd
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	4294000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-3826000	usd
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-845000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-135380000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-260082000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-284971000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	656860000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	11519000	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	179000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34303000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-284126000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-845000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	417890000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	433718000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	21441000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	90000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	43013000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-256256000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3826000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	656070000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	17810000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	92000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	52832000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-139674000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4294000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	591424000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-139674000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-256256000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-284126000	usd
CY2023	us-gaap	Depreciation Depreciation	528000	usd
CY2022	us-gaap	Depreciation Depreciation	656000	usd
CY2021	us-gaap	Depreciation Depreciation	533000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	52832000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	43013000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	34303000	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	92000	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	90000	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	179000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	8400000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-447000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	4080000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	38829000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	55033000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9391000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	26348000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	15972000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	892000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4457000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19749000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	11208000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1057000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1704000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3189000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	8287000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	8584000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3177000	usd
CY2023	itci	Increase Decrease In Accrued Customer Programs IncreaseDecreaseInAccruedCustomerPrograms	-27552000	usd
CY2022	itci	Increase Decrease In Accrued Customer Programs IncreaseDecreaseInAccruedCustomerPrograms	-19657000	usd
CY2021	itci	Increase Decrease In Accrued Customer Programs IncreaseDecreaseInAccruedCustomerPrograms	-2958000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4368000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2099000	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	5989000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1207000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	574000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-175000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-124199000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-270186000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-259544000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	415269000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	759209000	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	224575000	usd
CY2023	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	521079000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	631614000	usd
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	505244000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	269000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	778000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	325000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	105541000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-128373000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	280344000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	433718000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17810000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21441000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11519000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17810000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	455159000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11519000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-848000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	56600000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	32319000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150365000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93765000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61446000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	149517000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150365000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93765000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	162000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	6000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	6000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	419000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	108000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147767000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148615000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92365000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1750000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1750000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1400000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	149517000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.</span></div>
CY2022Q3	itci	Percentage Of Investments Qualified For Investment Tax Credit PercentageOfInvestmentsQualifiedForInvestmentTaxCredit	0.15
CY2023	itci	Average Annual Adjusted Income AverageAnnualAdjustedIncome	1000000000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. For the years ended December 31, 2023 and 2022, 97% of product sales were generated from three major industry wholesalers. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three individual customers accounted for approximately 36%, 32%, and 29% and 39%, 30%, and 28% of product sales for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, the Company believes that these customers are of high credit quality. </span></div>Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.005
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q3	itci	Percentage Of Investments Qualified For Investment Tax Credit PercentageOfInvestmentsQualifiedForInvestmentTaxCredit	0.25
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	412570000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	490000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	386000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	412674000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	490419000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	21000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4211000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	486229000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	77800000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	71500000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	165200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	70100000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	49100000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	389200000	usd
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	10700000	usd
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	12200000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	38621000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	17227000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4277000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2594000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7370000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4099000	usd
CY2023Q4	itci	Inventory Current And Noncurrent Net Of Reserves InventoryCurrentAndNoncurrentNetOfReserves	50268000	usd
CY2022Q4	itci	Inventory Current And Noncurrent Net Of Reserves InventoryCurrentAndNoncurrentNetOfReserves	23920000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	11647000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	23920000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	38621000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	0	usd
CY2023Q4	itci	Inventory Net Subject To Supplemental Regulatory Procedures InventoryNetSubjectToSupplementalRegulatoryProcedures	7700000	usd
CY2022Q4	itci	Inventory Net Subject To Supplemental Regulatory Procedures InventoryNetSubjectToSupplementalRegulatoryProcedures	0	usd
CY2023Q4	itci	Prepaid Operating Expenses Non Clinical PrepaidOperatingExpensesNonClinical	19465000	usd
CY2022Q4	itci	Prepaid Operating Expenses Non Clinical PrepaidOperatingExpensesNonClinical	11335000	usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets	15127000	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	21575000	usd
CY2023Q4	itci	Clinical Trial Advances ClinicalTrialAdvances	11630000	usd
CY2022Q4	itci	Clinical Trial Advances ClinicalTrialAdvances	11808000	usd
CY2023Q4	itci	Prefunded Customer Program PrefundedCustomerProgram	3514000	usd
CY2022Q4	itci	Prefunded Customer Program PrefundedCustomerProgram	561000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	49736000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	45279000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	42443000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	45193000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7293000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	86000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	3851000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	4719000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	5774000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	1536000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1612000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	2676000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2298000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	873000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2023	us-gaap	Lease Cost LeaseCost	7685000	usd
CY2022	us-gaap	Lease Cost LeaseCost	7204000	usd
CY2021	us-gaap	Lease Cost LeaseCost	8450000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0907
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0876
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3792000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3907000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3974000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4022000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	4144000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1771000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	21610000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4672000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	16938000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3612000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13326000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	52832000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	43013000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	34303000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.748
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.780
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.787
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.887
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.894
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.949
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0392
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0222
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0087
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	33.49
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	41.71
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	29.01
CY2023	itci	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term2 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2	P5Y9M18D
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	48.13
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	791795	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	22.49
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	39854	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	51.05
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	3425	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	40.94
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4239982	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.22
CY2023	itci	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm	P5Y2M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4239982	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	28.22
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3470018	shares
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-32785000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-62904000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-139038000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-256250000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	23.55
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y6M
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	15800000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	27187000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	48267000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	19688000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	184027000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	130078000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	172964000	usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	166820000	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	118340000	usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	131235000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	19120000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	17145000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	10583000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-139038000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-223465000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-221216000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-284120000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	636000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-51341000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-52789000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-53070000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-51341000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-52789000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-53070000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	636000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.019
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.006
CY2023	itci	Effective Income Tax Rate Reconciliation Subpart Finclusion EffectiveIncomeTaxRateReconciliationSubpartFinclusion	0
CY2022	itci	Effective Income Tax Rate Reconciliation Subpart Finclusion EffectiveIncomeTaxRateReconciliationSubpartFinclusion	-0.034
CY2021	itci	Effective Income Tax Rate Reconciliation Subpart Finclusion EffectiveIncomeTaxRateReconciliationSubpartFinclusion	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.027
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.046
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.016
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.002
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.003
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.036
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.020
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.141
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.015
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.369
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3000000	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	132099000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	126173000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	110792000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	95306000	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	166196000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	155886000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.206
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.187
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.005
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	528400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	138685000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	168606000	usd
CY2023Q4	itci	Deferred Tax Assets Tax Deferred Expense Accrued Expenses DeferredTaxAssetsTaxDeferredExpenseAccruedExpenses	17842000	usd
CY2022Q4	itci	Deferred Tax Assets Tax Deferred Expense Accrued Expenses DeferredTaxAssetsTaxDeferredExpenseAccruedExpenses	9169000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	31109000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9321000	usd
CY2023Q4	itci	Deferred Tax Assets Tax Deferred Expense Research And Development Expenses DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentExpenses	62432000	usd
CY2022Q4	itci	Deferred Tax Assets Tax Deferred Expense Research And Development Expenses DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentExpenses	13525000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	19753000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	17085000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1466000	usd
CY2023Q4	itci	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Capital Lease DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsCapitalLease	4198000	usd
CY2022Q4	itci	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Capital Lease DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsCapitalLease	4980000	usd
CY2023Q4	itci	Deferred Tax Liabilities Right Of Use Asset Capital Lease DeferredTaxLiabilitiesRightOfUseAssetCapitalLease	3204000	usd
CY2022Q4	itci	Deferred Tax Liabilities Right Of Use Asset Capital Lease DeferredTaxLiabilitiesRightOfUseAssetCapitalLease	3684000	usd
CY2023Q4	itci	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	140000	usd
CY2022Q4	itci	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	154000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	86000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2023Q4	itci	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	270589000	usd
CY2022Q4	itci	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	220314000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	270589000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	220314000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2500000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1700000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4300000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3900000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	157971000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	143698000	usd
CY2023Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	5966000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	5498000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	4530000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	4349000	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	448000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	135000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10000	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-28579000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-24258000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-42784000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-44053000	usd
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	87869000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	71870000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55579000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34996000	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	135281000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	127499000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	143502000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	107658000	usd
CY2022Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	3386000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2122000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1320000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	548000	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-44026000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-53508000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-86603000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-72119000	usd
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78

Files In Submission

Name	View Source	Status
0001628280-24-006156-index-headers.html	Edgar Link	pending
0001628280-24-006156-index.html	Edgar Link	pending
0001628280-24-006156.txt	Edgar Link	pending
0001628280-24-006156-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
itci-20231231.htm	Edgar Link	pending
itci-20231231.xsd	Edgar Link	pending
itci-20231231xex1035.htm	Edgar Link	pending
itci-20231231xex231.htm	Edgar Link	pending
itci-20231231xex311.htm	Edgar Link	pending
itci-20231231xex312.htm	Edgar Link	pending
itci-20231231xex321.htm	Edgar Link	pending
itci-20231231xex42.htm	Edgar Link	pending
itci-20231231_g1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
itci-20231231_cal.xml	Edgar Link	unprocessable
itci-20231231_def.xml	Edgar Link	unprocessable
itci-20231231_lab.xml	Edgar Link	unprocessable
itci-20231231_pre.xml	Edgar Link	unprocessable
itci-20231231_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ITCI
Intra-Cellular Therapies, Inc. Stock $itci

2024 Q1 Form 10-K Financial Statement

#000162828024006156 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITCI Intra-Cellular Therapies, Inc. Stock $itci

2024 Q1 Form 10-K Financial Statement

#000162828024006156 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITCI
Intra-Cellular Therapies, Inc. Stock $itci